QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · patients with functional dyspepsia
1 finding from 1 review
Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF
Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in quality of life CDLQI ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
1 finding from 1 review
Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported health‐related quality of life (0‐100 scale) Higher… compared with placebo (low certainty).
1 finding from 1 review